Evidence map›Paper›PMID 31173649›Full record

ArticleClinical pharmacology and therapeutics2019

Reduced Exposure to Piperaquine, Compared to Adults, in Young Children Receiving Dihydroartemisinin-Piperaquine as Malaria Chemoprevention.

Meghan E Whalen, Richard Kajubi, Nona Chamankhah, Liusheng Huang, Francis Orukan, Erika Wallender, Moses R Kamya, Grant Dorsey, Prasanna Jagannathan, Philip J Rosenthal and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical pharmacology and therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Meghan E WhalenDepartment of Clinical Pharmacy, University of California San Francisco, San Francisco General Hospital, San Francisco, California, USA.
Richard KajubiInfectious Disease Research Collaboration, Makerere University College of Health Sciences, Kampala, Uganda.
Nona ChamankhahDepartment of Pharmacy, Rady Children's Hospital, San Diego, California, USA.
Liusheng HuangDepartment of Clinical Pharmacy, University of California San Francisco, San Francisco General Hospital, San Francisco, California, USA.
Francis OrukanInfectious Disease Research Collaboration, Makerere University College of Health Sciences, Kampala, Uganda.
Erika WallenderDepartment of Medicine, University of California San Francisco, San Francisco General Hospital, San Francisco, California, USA.
Moses R KamyaInfectious Disease Research Collaboration, Makerere University College of Health Sciences, Kampala, Uganda.
Grant DorseyDepartment of Medicine, University of California San Francisco, San Francisco General Hospital, San Francisco, California, USA.
Prasanna JagannathanDepartment of Medicine, Stanford University, Stanford, California, USA.
Philip J RosenthalDepartment of Medicine, University of California San Francisco, San Francisco General Hospital, San Francisco, California, USA.
Norah MwebazaInfectious Disease Research Collaboration, Makerere University College of Health Sciences, Kampala, Uganda.
Francesca T AweekaDepartment of Clinical Pharmacy, University of California San Francisco, San Francisco General Hospital, San Francisco, California, USA.
Makerere University · UGUniversity of California, San Francisco · USSan Francisco General Hospital · USRady Children's Hospital-San Diego · USStanford University · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 1988 to 2026
$93.6M
The immunologic consequences of prenatal exposure to malariaP01HD059454 · NICHD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAVLIR, DIANE V · 2008 to 2017
$22.6M
Pharmacological insights into antimalarial exposure, clinical outcomes, and drug resistance in AfricaR01AI117001 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AWEEKA, FRANCESCA T., ROSENTHAL, PHILIP JON · 2015 to 2024
$7.1M
NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI117001NICHD NIH HHS P01 HD059454
6 · The paper itself

Abstract

Dihydroartemisinin (DHA)-piperaquine is being evaluated as intermittent preventive therapy for malaria, but dosing has not been optimized for children. We assessed exposure to DHA and piperaquine in Ugandan children at two ages during infancy. Intensive sampling was performed in 32 children at 32 weeks of age, 31 children at 104 weeks, and 30 female adult controls. Compared with adults, DHA area under the concentration-time curve (AUC

Indexed as

AdultAge FactorsAntimalarialsArtemisininsChemopreventionChild, PreschoolFemaleHumansInfantMalaria, FalciparumMalePiperazinesQuinolinesYoung AdultAntimalarialsArtemisininsartenimolpiperaquinePiperazinesQuinolines

Identifiers

PMID31173649
PMCPMC6851416
OpenAlexW2960895286

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.